2012 Tuberous Sclerosis Complex Clinical Trial Award Program
Page 2

With this, the funding agency requires the proposals to be submitted under this program to focus on the following areas:

a) The studies of the pathogenesis, disease severity prediction and diversity of symptoms that affects a patient's cognition, behavior, sleep, renal and pulmonary functions, along with the signs and symptoms of epilepsy and autism

b) The studies regarding the impact of TSC manifestations over the lifespan of a patient

c) The determination of novel strategies for the management and prevention of TSC manifestations including early therapeutic approaches

d) The deep comprehension of the cellular and molecular mechanisms of TSC developmental stages in mammalian and non-mammalian systems

e) Genetic, epigenetic, and non-genetic modifiers of TSC

f) The identification of biomarkers for early detection, prognosis, and prediction of TSC treatment outcomes.

To support this activities covered under this initiative, the Department of Defense is willing to administer funds in the amount of $1,600,000 per year, for a maximum project period of up to 4 years.

Assistant Professors or Lead Professors at Accredited Colleges and Universities are encouraged to submit an application under the 2012 Tuberous Sclerosis Complex Clinical Trial Award Program.

2012 Tuberous Sclerosis Complex Clinical Trial Award Program
  Back to Page 1

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on community grants and health grants.

Additional Resources

category - Health Grants

Development of Therapeutics and Diagnostics for Biodefense Program
The National Institutes of Health, in partnership with the National Institute of Allergy and Infectious Diseases(NIAID), has established the Development of Therapeutics and Diagnostics for Biodefense Program in an attempt to seek research proposals that desire to support the development of lead candidate diagnostics or therapeutics against NIAID Category A, B, or C priority agents.

---

Mechanisms Mediating Osteoarthritis in Aging
The National Institutes of Health, in close cooperation with The National Institute on Aging and the National Institute of Arthritis and Musculoskeletal and Skin Diseases, has recently established a program called Mechanisms Mediating Osteoarthritis in Aging in an effort to improve and encourage the characterization of new and underutilized models in order to gain a deeper understanding of mechanisms that are involved in osteoarthritic progression.

---

Health Resources and Services Administration: Affordable Care Act - Immediate Facility Improvements Program
The HRSA administers health care grants to eligible individuals, in order to help them obtain safe and quality care through the Affordable Care Act Capital Development (Immediate Facility Improvements Program).

---

Health Care Innovation Challenge
The Centers for Medicare and & Medicaid Services has recently established the Health Care Innovation Challenge in an attempt to solicit proposals to establish interesting new models of service delivery that can potentially deliver the three-part aim of better health, better health care, and finally, lower costs through the improved quality of Medicare, Medicaid, and Children's Health Insurance Program.

---